From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

Special to Wesson NewsIn celebration of a decade of powerful advocacy and progress, Wesson resident and lung cancer advocate ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to ...

Lung cancer screening with low-dose CT could have saved tens of thousands of lives — if only we'd listened to the data back ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Since its inception, LUNG FORCE has played a pivotal role in transforming the landscape of lung cancer research, treatment and awareness. Over the past 10 years, the American Lung Association has ...